[REVISION HISTORY]

AbbVie financial performance and strategic transition

1 recorded revision of this situation.

What changed

2026-10-30 14:29 UTC → 2026-10-31 15:48 UTC · added ~~removed~~

AbbVie is undergoing a strategic shift in its pharmaceutical focus, moving from its legacy product Humira toward new immunology and oncology treatments. In fiscal year 2025, the company reported revenue of $61.2 billion, representing an 8.6% increase from the previous year, with a net income of $4.2 billion. The company also announced a quarterly dividend of $1.73 per share. Following strong third-quarter ~~results,~~ results in 2026, AbbVie raised its annual adjusted profit guidance to a range of $13.95 to $13.99 per share. Quarterly revenue reached $17.4 billion, a 10.3% year-over-year increase that exceeded analyst expectations. This growth was largely driven by the immunology franchise, specifically Skyrizi and Rinvoq, which helped offset declining sales of Humira due to the loss of patent exclusivity. Skyrizi generated $5.78 billion in revenue, while Rinvoq brought in $2.71 billion. Additionally, the neuroscience division saw a 19% revenue ~~increase.~~ increase, reaching $3.39 billion, supported by Botox Therapeutic and Vraylar. To strengthen its long-term pipeline, the company is utilizing acquisitions, including the $10.9 billion purchase of Apogee Therapeutics. The company also announced a 5.2% increase in its quarterly dividend, with higher payments scheduled to begin in February 2027.

Versions

Select a version to see what changed compared to the one before it.